# US 11,306,399 B2 · Nanoparticle compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,306,399 B2
- Document ID: US11306399B2
- Status: Granted
- Kind: B2
- Application number: 16/992,036
- Filed: 2020-08-12
- Published: 2021-02-18
- Granted: 2022-04-19
- Earliest claimed: 2019-08-13
- Assignees: January Therapeutics, Inc.
- Applicants: January Therapeutics, Inc.
- Inventors: Raj Raheja; Robin M. Jackman; Jason A. Kahana
- Web page: https://patentgrep.com/patent/US11306399B2

## CPC

- C23F 1/18: for etching copper or alloys thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61P 35/00: Antineoplastic agents
- C01B 32/194: After-treatment
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C23F 1/08: Apparatus, e.g. for photomechanical printing surfaces (photo- mechanical reproduction G03F)
- H01J 37/20: Means for supporting or positioning the object or the material; Means for adjusting diaphragms or lenses associated with the support
- C01B 2204/02: Single layer graphene
- C01B 2204/04: Specific amount of layers or specific thickness
- H01J 2235/183: Multi-layer structures
- H01J 2237/20: Positioning, supporting, modifying or maintaining the physical state of objects being observed or treated
- H01J 2237/26: Electron or ion microscopes
- C23F: NON-MECHANICAL REMOVAL OF METALLIC MATERIAL FROM SURFACE (working metal by laser beams B23K26/00; desurfacing by applying flames B23K7/00; working of metal by electro-erosion B23H; producing decorative effects by removing surface material, e.g. by engraving, by etching, B44C1/22; electrolytic etching or polishing C25F); INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL; MULTI-STEP PROCESSES FOR SURFACE TREATMENT OF METALLIC MATERIAL INVOLVING AT LEAST ONE PROCESS PROVIDED FOR IN CLASS C23 AND AT LEAST ONE PROCESS COVERED BY SUBCLASS C21D OR C22F OR CLASS C25
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- H01J: ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS (spark-gaps H01T; electric arc lamps H05B31/00; particle accelerators H05H)

## Abstract

Provided herein are nanoparticle compositions comprising an organophosphate compound and pharmaceutically acceptable carriers.

## Claims

### Claim 1

A compound that is:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

### Claim 3

A composition comprising nanoparticles, wherein the nanoparticles comprise a pharmaceutically acceptable carrier comprising albumin and a compound that is:

### Claim 4 (depends on 3)

The composition of claim 3, wherein the nanoparticles have an average diameter of from about 10 nm to about 1000 nm.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the nanoparticles have an average diameter of from about 30 nm to about 250 nm.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the albumin is human serum albumin.

### Claim 7 (depends on 3)

The composition of claim 3, wherein the molar ratio of the compound to pharmaceutically acceptable carrier is from about 1:1 to about 20:1.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the molar ratio of the compound to pharmaceutically acceptable carrier is from about 2:1 to about 12:1.

### Claim 9 (depends on 3)

The composition of claim 3, wherein the composition is dehydrated.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the composition is a lyophilized composition.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the composition comprises from about 0.9% to about 24% by weight of the compound.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the composition comprises from about 76% to about 99% by weight of the pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the composition comprises from about 84% to about 98% by weight of the pharmaceutically acceptable carrier.

### Claim 14 (depends on 10)

The composition of claim 10, wherein the composition is reconstituted with a biocompatible liquid to provide a reconstituted composition.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the biocompatible liquid is a buffered solution, a solution comprising dextrose, or a solution comprising one or more salts.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the biocompatible liquid is sterile water, saline, phosphate-buffered saline, 5% dextrose in water solution, Ringer's solution, or Ringer's lactate solution.

### Claim 17 (depends on 14)

The composition of claim 14, wherein the nanoparticles have an average diameter of from about 10 nm to about 1000 nm after reconstitution.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the nanoparticles have an average diameter of from about 30 nm to about 250 nm after reconstitution.